Vivesto AB (OSTO:VIVE) FCF Yield %: -38.87 (As of Jul. 03, 2026)


OSTO:VIVE Vivesto AB OSTO:VIVE
26 GF Score
Price kr8.40
! 1 Warning Sign
View Full Analysis

What is Vivesto AB FCF Yield %?

Vivesto AB OSTO:VIVE -3.40% 26 FCF Yield % is -38.87 as of Jul. 03, 2026. GuruFocus rates OSTO:VIVE with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,006 Drug Manufacturers companies, Vivesto AB ranks worse than 94.33% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Vivesto AB's Trailing 12-Month Free Cash Flow is kr-36.17 Mil, and Market Cap is kr93.04 Mil. Therefore, Vivesto AB's FCF Yield % for today is -38.87%.

The historical rank and industry rank for Vivesto AB's FCF Yield % or its related term are showing as below:

OSTO:VIVE' s FCF Yield % Range Over the Past 10 Years
Min: -191.4   Med: -23.16   Max: -0.58
Current: -38.87


During the past 13 years, the highest FCF Yield % of Vivesto AB was -0.58%. The lowest was -191.40%. And the median was -23.16%.

OSTO:VIVE's FCF Yield % is ranked worse than
94.33% of 1006 companies
in the Drug Manufacturers industry
Industry Median: 0.665 vs OSTO:VIVE: -38.87

Vivesto AB's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.


Vivesto AB FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Vivesto AB FCF Yield % Related Terms


Vivesto AB FCF Yield % Historical Data

* Premium members only.

The historical data trend for Vivesto AB's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivesto AB FCF Yield % Chart

Vivesto AB Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.30 -36.83 -31.65 -30.28 -60.32

Vivesto AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.51 -63.89 -9.08 -40.11 -28.99

OSTO:VIVE vs ZTS, UTHR, VTRS: FCF Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivesto AB FCF Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Vivesto AB's FCF Yield % falls into.


OSTO:VIVE
26GF Score
Vivesto AB OSTO:VIVE
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivesto AB FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Vivesto AB's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-43.813 / 72.6385
=-60.32%

Vivesto AB's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-6.46 * 4 / 89.12155
=-28.99%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -38.87 mean?
Vivesto AB (OSTO:VIVE) has a FCF Yield % of -38.87 as of Jul. 03, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vivesto AB and its competitors. According to the industry distribution chart, Vivesto AB ranks #949 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 94.3%.
Is Vivesto AB's FCF Yield % too high?
Vivesto AB's current FCF Yield % is -38.87. Based on the distribution chart, Vivesto AB ranks #949 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivesto AB ranks #949 out of 1006 companies for FCF Yield %. This places Vivesto AB in the lower half of its industry. The industry median FCF Yield % is 0.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vivesto AB and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivesto AB's current FCF Yield % is -38.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OSTO:VIVE) has a current FCF Yield % of -38.87. The current FCF Yield % is -38.87. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Vivesto AB (OSTO:VIVE), the current FCF Yield % is -38.87 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivesto AB Business Description

Other Exchanges OMA:Germany
Address Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score

Get the complete analysis for OSTO:VIVE

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr8.40
Price